Zemidapa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Zemidapa, do not provide adequate glycaemic control; when already being treated with the free combination of dapagliflozin and gemigliptin (see Pharmacology: Pharmacodynamics under Actions).